Thermo Fisher Scientific (NYSE:TMO) Lowered to Hold Rating by Wall Street Zen

Thermo Fisher Scientific (NYSE:TMO) was downgraded by research analysts at Wall Street Zen from a “buy” rating to a “hold” rating in a research report issued to clients and investors on Saturday.

TMO has been the topic of several other research reports. Wells Fargo & Company set a $683.00 price target on shares of Thermo Fisher Scientific in a research report on Friday. Redburn Partners set a $580.00 target price on Thermo Fisher Scientific in a report on Wednesday, October 8th. Leerink Partners boosted their price target on Thermo Fisher Scientific from $545.00 to $580.00 and gave the stock an “outperform” rating in a report on Wednesday, October 22nd. Argus raised their price objective on Thermo Fisher Scientific from $580.00 to $610.00 and gave the company a “buy” rating in a research note on Wednesday, October 29th. Finally, UBS Group reissued a “neutral” rating and issued a $615.00 target price on shares of Thermo Fisher Scientific in a report on Friday. One equities research analyst has rated the stock with a Strong Buy rating, eighteen have given a Buy rating and three have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $633.68.

Thermo Fisher Scientific Stock Performance

NYSE:TMO opened at $578.20 on Friday. The company has a market cap of $217.24 billion, a price-to-earnings ratio of 32.59, a PEG ratio of 3.89 and a beta of 0.91. Thermo Fisher Scientific has a fifty-two week low of $385.46 and a fifty-two week high of $643.99. The company has a debt-to-equity ratio of 0.67, a quick ratio of 1.11 and a current ratio of 1.89. The stock has a fifty day moving average price of $593.96 and a 200-day moving average price of $537.07.

Thermo Fisher Scientific (NYSE:TMO) last posted its quarterly earnings results on Thursday, January 29th. The medical research company reported $6.57 EPS for the quarter, beating analysts’ consensus estimates of $6.45 by $0.12. The business had revenue of $12.22 billion during the quarter, compared to the consensus estimate of $11.95 billion. Thermo Fisher Scientific had a return on equity of 16.92% and a net margin of 15.05%.Thermo Fisher Scientific’s revenue for the quarter was up 7.2% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $6.10 earnings per share. As a group, equities analysts anticipate that Thermo Fisher Scientific will post 23.28 EPS for the current fiscal year.

Thermo Fisher Scientific declared that its Board of Directors has initiated a share repurchase plan on Thursday, November 6th that allows the company to repurchase $5.00 billion in shares. This repurchase authorization allows the medical research company to buy up to 2.4% of its stock through open market purchases. Stock repurchase plans are generally an indication that the company’s board of directors believes its shares are undervalued.

Insider Buying and Selling at Thermo Fisher Scientific

In related news, VP Lisa P. Britt sold 1,058 shares of the stock in a transaction on Wednesday, November 12th. The stock was sold at an average price of $588.26, for a total value of $622,379.08. Following the completion of the sale, the vice president directly owned 13,087 shares in the company, valued at $7,698,558.62. This represents a 7.48% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, COO Michel Lagarde sold 22,046 shares of the company’s stock in a transaction dated Thursday, December 4th. The shares were sold at an average price of $563.56, for a total value of $12,424,243.76. Following the completion of the sale, the chief operating officer owned 84,117 shares in the company, valued at $47,404,976.52. This trade represents a 20.77% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders sold 124,517 shares of company stock valued at $72,363,568. 0.33% of the stock is owned by insiders.

Institutional Trading of Thermo Fisher Scientific

Several institutional investors have recently added to or reduced their stakes in the stock. JPL Wealth Management LLC acquired a new position in shares of Thermo Fisher Scientific in the 3rd quarter worth approximately $28,000. Highline Wealth Partners LLC lifted its holdings in Thermo Fisher Scientific by 126.9% in the third quarter. Highline Wealth Partners LLC now owns 59 shares of the medical research company’s stock valued at $29,000 after buying an additional 33 shares during the period. Beacon Financial Strategies CORP bought a new stake in Thermo Fisher Scientific during the fourth quarter valued at $29,000. Olistico Wealth LLC acquired a new stake in Thermo Fisher Scientific during the 4th quarter worth about $29,000. Finally, Capital A Wealth Management LLC increased its holdings in Thermo Fisher Scientific by 825.0% in the second quarter. Capital A Wealth Management LLC now owns 74 shares of the medical research company’s stock worth $30,000 after purchasing an additional 66 shares in the last quarter. 89.23% of the stock is currently owned by institutional investors.

More Thermo Fisher Scientific News

Here are the key news stories impacting Thermo Fisher Scientific this week:

• Positive Sentiment: Q4 results beat expectations — Adjusted EPS $6.57 and revenue $12.21B (≈+7% YoY), driven by life-sciences tools and pharma demand; the print supports near-term organic growth narrative. Read More.
• Positive Sentiment: Analyst support remains — several firms reiterated buys/positive views and one bullish write-up called the pullback a buying opportunity, highlighting resilient margins and competitive positioning. Read More.
• Neutral Sentiment: 2026 guidance set in a narrow band — FY26 revenue guide $46.3B–$47.2B and EPS $24.22–$24.80, roughly around consensus but slightly below EPS midpoint; guidance implies modest 3%–4% organic growth and stabilizing demand. Read More.
• Negative Sentiment: Market reaction focused on cautious profit outlook and margin pressure — despite the beat, investors sold into the print due to conservative margin commentary and a guidance range that doesn’t accelerate growth significantly. Read More.
• Negative Sentiment: Analyst price-target trim — TD Cowen lowered its PT from $696 to $683 while keeping a Buy rating, signaling slightly reduced upside expectations even as coverage stays positive. Read More.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.